HomeCompareREGMF vs DGRO

REGMF vs DGRO: Dividend Comparison 2026

REGMF yields 18.27% · DGRO yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 REGMF wins by $34.0K in total portfolio value
10 years
REGMF
REGMF
● Live price
18.27%
Share price
$10.95
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$65.6K
Annual income
$5,575.28
Full REGMF calculator →
DGRO
iShares Core Dividend Growth ETF
● Live price
2.13%
Share price
$68.98
Annual div
$1.47
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.6K
Annual income
$239.96
Full DGRO calculator →

Portfolio growth — REGMF vs DGRO

📍 REGMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodREGMFDGRO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, REGMF + DGRO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
REGMF pays
DGRO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

REGMF
Annual income on $10K today (after 15% tax)
$1,552.64/yr
After 10yr DRIP, annual income (after tax)
$4,738.99/yr
DGRO
Annual income on $10K today (after 15% tax)
$181.24/yr
After 10yr DRIP, annual income (after tax)
$203.97/yr
At 15% tax rate, REGMF beats the other by $4,535.02/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of REGMF + DGRO for your $10,000?

REGMF: 50%DGRO: 50%
100% DGRO50/50100% REGMF
Portfolio after 10yr
$48.6K
Annual income
$2,907.62/yr
Blended yield
5.98%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

REGMF buys
0
DGRO buys
0
No recent congressional trades found for REGMF or DGRO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricREGMFDGRO
Forward yield18.27%2.13%
Annual dividend / share$2.00$1.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$65.6K$31.6K
Annual income after 10y$5,575.28$239.96
Total dividends collected$35.6K$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: REGMF vs DGRO ($10,000, DRIP)

YearREGMF PortfolioREGMF Income/yrDGRO PortfolioDGRO Income/yrGap
1← crossover$12,527$1,826.63$11,293$213.22+$1.2KREGMF
2$15,542$2,138.47$12,730$217.32+$2.8KREGMF
3$19,110$2,479.65$14,326$221.10+$4.8KREGMF
4$23,297$2,849.38$16,098$224.56+$7.2KREGMF
5$28,174$3,246.45$18,064$227.74+$10.1KREGMF
6$33,815$3,669.26$20,246$230.65+$13.6KREGMF
7$40,298$4,115.87$22,666$233.30+$17.6KREGMF
8$47,703$4,584.06$25,349$235.73+$22.4KREGMF
9$56,114$5,071.40$28,325$237.94+$27.8KREGMF
10$65,617$5,575.28$31,624$239.96+$34.0KREGMF

REGMF vs DGRO: Complete Analysis 2026

REGMFStock

RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, Sjögren's syndrome, multiple sclerosis, and myasthenia gravis; RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC98, a PD-L1 monoclonal antibody for the treatment of solid tumors and is under Phase I clinical trial; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors, as well as lung and urothelial cancer; and RC108 that is in Phase 1 clinical trials to treat various solid tumors. In addition, the company's products under pre-clinical development include RC118, RC138, RC148, RC158, RC168, RC178, RC188, and RC198 to treat various solid tumors; and RC208, RC218, and RC228 to treat ophthalmic diseases. RemeGen Co., Ltd. was incorporated in 2008 and is headquartered in Yantai, the People's Republic of China.

Full REGMF Calculator →

DGROETF

The iShares Core Dividend Growth ETF seeks to track the investment results of an index composed of U.S. equities with a history of consistently growing dividends.

Full DGRO Calculator →
📬

Get this REGMF vs DGRO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

REGMF vs SCHDREGMF vs JEPIREGMF vs OREGMF vs KOREGMF vs MAINREGMF vs VIGREGMF vs NOBLREGMF vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.